



**National Institute for
Health and Clinical Excellence**

28 October 2008

Level 1 City Tower
Piccadilly Plaza
Manchester
M1 4BD

PER EMAIL

Tel: 0845 003 7780
Fax: 0845 003 7785
Email: nice@nice.org.uk
www.nice.org.uk

Dear consultees and commentators,

**Health Technology Appraisal
Drugs for the treatment of pulmonary arterial hypertension**

NICE is proposing to reissue the scope and remit for the appraisal of drugs for the treatment of pulmonary arterial hypertension and we are consulting with consultees and commentators on a draft of the new scope and remit.

We have also updated the matrix of stakeholders for this appraisal. We are inviting comments from organisations who were unable to participate previously or who chose not to and from organisations who we did not invite but who may be interested in this appraisal.

The attached letter has more information on why we are proposing to change the scope.

We are now seeking your comments on a new draft remit and draft scope for this appraisal. After consideration of comments on the drafts, a final remit and scope will be issued. Consultees will be invited to make further submissions of evidence based on the new final scope.

Please find attached the following documents:

- Letter to consultees and commentators explaining the reasons behind the proposed change;
- Appendix A – draft remit and draft scope for the proposed appraisal;
- Appendix B – an updated matrix of consultees and commentators for the proposed appraisal;
- Appendix C – procedure note;
- Comment form – for you to complete and return;
- Contact details form – for you to complete and return.

Please return the forms, preferably by e-mail, to david.bevan@nice.org.uk by 5pm on **25 November 2008**.

Yours faithfully

Dr Carole Longson,
Director Centre for Health Technology Evaluation